Skip to main content
. Author manuscript; available in PMC: 2018 Mar 5.
Published in final edited form as: J Neuroimmune Pharmacol. 2011 Jun 14;6(4):585–596. doi: 10.1007/s11481-011-9284-5

FIGURE 9.

FIGURE 9

Changes in Tb after ICV IL-1β or aCSF (CON) exposure. Rats (n=12/group) were implanted with biotelemeters to monitor Tb as described in Materials and Methods. Seven days post-implantation, animals were given IL-1β (100 ng/d/kg) or aCSF (CON) via ICV cannulas in the morning. Average changes in Tb are shown for CON and IL-1β-treated animals 1 day before IL-1β/aCSF administration and 1, 7, and 10 days post IL-1β/aCSF ICV exposure. The horizontal bar over the X-axis indicates the dark (active) phase of the light/dark cycle.